Drug Profile

TATX 20

Alternative Names: TATX-20

Latest Information Update: 19 Mar 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

19 Mar 2025 Preclinical trials in Cancer in USA (Parenteral) prior to March 2025 (Talem Therapeutics pipeline, March 2025)
03 Feb 2025 Biotheus has been acquired by BioNTech
02 Oct 2024 Biotheus obtains the rights to evaluate the suitability of TATX 20 for the development of novel bispecific antibodies for the treatment of hypoxic solid tumors from ImmunoPrecise

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com